NexGel raises $1.21M via insider-backed convertible notes
What's the deal? NexGelDealroom has a profile for this one. Try Dealroom →, a small-cap company that develops hydrogel products, raised $1.21M through a private placement of unsecured convertible promissory notes and warrants between May 11 and May 14, 2026. The notes convert at $0.60 per share and the warrants are exercisable at $0.80. The bulk of the funding — $1.085M of the $1.21M — came from company insiders, including directors and the chief executive officer.
Why now? NexGel needs working capital and liquidity to keep operations running. The company, which has a market cap of just $6.2M, structured this raise to align with terms from an earlier financing round on April 17, 2026, while stripping out prior additional-purchase and escrow mechanics to simplify the process.
What could go wrong? NexGel's fundamentals raise red flags. The company faces ongoing losses, negative cash flow, and rising leverage. Its stock trades below key moving averages, and it has received a Nasdaq bid-price deficiency notice — meaning it risks being delisted if the share price doesn't recover. With insiders providing nearly 90% of the capital, outside investor appetite appears limited.
The convertible notes and warrants also create future dilution for existing shareholders if converted into common stock.
The signal: NexGel sits at the intersection of hydrogel-based transdermal delivery and, via its BioNXDealroom has a profile for this one. Try Dealroom → acquisition, bioresonance therapy — both early-growth niches without deep public-market investor pools. That nearly 90% of this round came from insiders underscores how difficult it remains for micro-cap medtech companies to attract outside capital, particularly when trading under Nasdaq's minimum bid-price threshold. The $0.60 conversion price and $0.80 warrant strike effectively set a floor that management is betting on, but the gap between that floor and the single analyst's $2.00 target tells its own story about the uncertainty ahead.
Read more: blog.tipranks.com
